EP Patent

EP3529360B1 — Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction

Assigned to Novartis AG · Expires 2024-04-17 · 2y expired

What this patent protects

Patent listed against Colcrys.

Drugs covered by this patent

Patent Metadata

Patent number
EP3529360B1
Jurisdiction
EP
Classification
—
Expires
2024-04-17
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.